Abstract
Mepolizumab is an IL-5 antagonist mAb indicated for add-on maintenance treatment for patients with severe eosinophilic asthma and refractory eosinophilic granulomatosis with polyangiitis.1 The Steroid Reduction with Mepolizumab Study (SIRIUS) trial (NCT01691508) demonstrated that mepolizumab reduced the maintenance oral corticosteroid (OCS) dose required for OCS-dependent patients with severe eosinophilic asthma, as well as the exacerbation rate.2 Other phase 2 and 3 trials including Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) (NCT01691521), Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control (MUSCA) (NCT02281318), and Dose Ranging Efficacy and Safety with Mepolizumab in Severe Asthma (DREAM) (NCT01000506) showed that mepolizumab plus standard of care therapy reduced exacerbations in patients with severe eosinophilic asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
